Inhibitory effects of dobutamine on human gastric adenocarcinoma

Hui-Xia Zheng1, Li-Na Wu1, Hong Xiao1

  • 1Hui-Xia Zheng, Li-Na Wu, Hong Xiao, Qian Du, Jian-Fang Liang, Department of Pathology, The First Hospital, Shanxi Medical University, Taiyuan 030024, Shanxi Province, China.

Abstract

Insights

Dobutamine effectively inhibits gastric adenocarcinoma cell growth, migration, and invasion. This drug also induces apoptosis and cell cycle arrest, suggesting potential as a neoadjuvant therapy for gastric cancer.

Area of Science:

  • Oncology
  • Cancer Biology
  • Pharmacology

Background:

  • Gastric adenocarcinoma is a significant global health concern.
  • Exploring novel therapeutic agents for gastric cancer is crucial.

Purpose of the Study:

  • To investigate the inhibitory effects of dobutamine on gastric adenocarcinoma cells.
  • To evaluate dobutamine's impact on cell viability, proliferation, migration, invasion, cell cycle, and apoptosis.

Main Methods:

  • Utilized gastric adenocarcinoma cells (SGC-7901) treated with dobutamine.
  • Assessed cell viability (MTT assay), migration (wound healing), proliferation (colony formation), invasion (Transwell assay).
  • Analyzed cell cycle and apoptosis (flow cytometry), and Yes-associated protein (YAP) expression (Western blot, immunocytochemistry).

Main Results:

  • Dobutamine significantly inhibited cell growth, migration, colony formation, and invasion.
  • Dobutamine induced G1/S phase cell cycle arrest and increased apoptosis.
  • Dobutamine treatment altered YAP expression, with reduced phosphorylated YAP in the cytosol.

Conclusions:

  • Dobutamine exhibits significant inhibitory effects on gastric adenocarcinoma cells.
  • Dobutamine shows promise as a neoadjuvant therapy for gastric cancer and potentially other tumors.

Related Concept Videos

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.9K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
4.7K
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
8.4K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
1.3K
Gastric Emptying01:16

Gastric Emptying

Gastric emptying occurs when the stomach gradually releases chyme into the duodenum. When the stomach is distended, it triggers the release of gastrin, a hormone that promotes gastric acid secretion to aid in digestion. Additionally, stomach distension contributes to peristaltic waves that propel gastric contents toward the pyloric region. The gastroenteric reflex, on the other hand, primarily stimulates peristalsis in the intestines, facilitating the movement of contents further along the...
5.5K